SCHEMBL260982

SCHEMBL260982

O=C(O)n1ncc2ccccc21

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 1/20 0.54
ELANE P08246 1/20 0.54
TFPI2 P48307 1/20 0.54
KMO O15229 1/20 0.53
ASAH1 Q13510 2/20 0.52
RECQL P46063 2/20 0.46
PKM P14618 1/20 0.45
DAO P14920 1/20 0.43
CHEK1 O14757 1/20 0.41
AURKA O14965 1/20 0.41
DAPK3 O43293 1/20 0.41
CSNK1A1 P48729 1/20 0.41
GSK3A P49840 1/20 0.41
LIMK1 P53667 1/20 0.41
IKBKE Q14164 1/20 0.41
MAPK14 Q16539 1/20 0.41
TAOK1 Q7L7X3 1/20 0.41
CLK4 Q9HAZ1 1/20 0.41
DYRK1B Q9Y463 1/20 0.41
CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL30581596 0.98 SLC22A12 (0.53) SLC22A12ELANETFPI2KMOASAH1
SCHEMBL4423022 0.86 SLC22A12 (0.55) SLC22A12ELANETFPI2KMOASAH1
SCHEMBL496975 0.83 ELANE (0.70) SLC22A12ELANETFPI2KMOASAH1
SCHEMBL2025416 0.82 SLC22A12 (0.56) SLC22A12ELANETFPI2KMOASAH1
SCHEMBL1087434 0.82 CHEK1 (0.60) SLC22A12ELANETFPI2KMOASAH1
Indazole Carboxamide SCHEMBL42505 0.82 SLC22A12 (0.53) SLC22A12ELANETFPI2KMOASAH1
SCHEMBL300192 0.82 TFPI2 (0.49) SLC22A12ELANETFPI2KMOASAH1
SCHEMBL29238955 0.82 ELANE (0.68) SLC22A12ELANETFPI2KMOASAH1
SCHEMBL6066049 0.81 TDP1 (0.44) SLC22A12ELANETFPI2KMOASAH1
Indazole Carboxamide SCHEMBL15638369 0.81 SLC22A12 (0.51) SLC22A12ELANETFPI2KMOASAH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 396 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3924340-B1 INDAZOLYL-ISOXAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER MERCK PATENT GMBH (DE) 2025-01-29 EP claimed
WO-2023168298-A2 COMPOUNDS, COMPOSITIONS, AND METHODS DENALI THERAPEUTICS INC. (US) 2023-09-07 WO claimed
EP-2903978-B1 GDF-8 INHIBITORS RIGEL PHARMACEUTICALS INC (US) 2022-12-07 EP claimed
CN-112979672-B 11, 20-dicarbonyl oridonin 14-O esterified series derivatives and application thereof 郑州大学 2022-03-11 CN claimed
EP-3288940-B9 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2021-07-21 EP claimed
CN-112979672-A 11, 20-dicarbonyl oridonin 14-O esterified series derivatives and application thereof 郑州大学 2021-06-18 CN claimed
EP-3288940-B1 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2021-02-24 EP claimed
EP-3134408-A1 FACTOR XIa INHIBITORS Merck Sharp & Dohme Corp. (US) 2017-03-01 EP claimed
WO-2015164308-A1 FACTOR XIa INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-10-29 WO claimed
EP-2797597-A1 SUBSTITUTED HETEROARYL ALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION Global Blood Therapeutics, Inc. (US) 2014-11-05 EP claimed
WO-2006044528-A1 PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2006-04-27 WO claimed
US-20060052417-A1 Indazolamides with analgesic activity AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2006-03-09 US claimed
EP-1622892-A1 INDAZOLES HAVING ANALGESIC ACTIVITY AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. (IT) 2006-02-08 EP claimed
EP-1594859-A1 INDAZOLAMIDES WITH ANALGESIC ACTIVITY AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. (IT) 2005-11-16 EP claimed
US-20050107399-A1 Cytokine inhibitors KEMIA, INC. 2005-05-19 US claimed
WO-2005023761-A2 CYTOKINE INHIBITORS KEMIA, INC. (US) 2005-03-17 WO claimed
WO-2005016890-A1 FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR ABBOTT LABORATORIES (US) 2005-02-24 WO claimed
WO-2004111009-A1 FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR ABBOTT LABORATORIES (US) 2004-12-23 WO claimed
WO-2004101548-A1 INDAZOLE HAVING ANALGESIC ACTIVITY , AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2004-11-25 WO claimed
WO-2004074275-A1 INDAZOLAMIDES WITH ANALGESIC ACTIVITY AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2004-09-02 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107399-A1 Cytokine inhibitors TNF, IL1RN, IL1A SLC22A12 3976/4885ELANE 338/4885TFPI2 111/4885
US-20060052417-A1 Indazolamides with analgesic activity P2RX7, P2RX3, P2RX1 SLC22A12 1356/4885ELANE 1812/4885TFPI2 3816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.